OssDsign® Catalyst receives clearance from FDA for major new indication for use in interbody cages
Uppsala, Sweden, September 18, 2023. OssDsign AB (publ.) today announces that the company’s innovative nanosynthetic bone graft OssDsign Catalyst has received clearance for use in interbody cages in spinal surgery from the U.S. Food and Drug Administration (FDA), allowing surgeons to use OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone.“This decision by the FDA represents one of the most important events in the history of